| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911036 | Lung Cancer | 2013 | 6 Pages |
Abstract
The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
T. Ciuleanu, C.-M. Tsai, C.-J. Tsao, J. Milanowski, D. Amoroso, D.S. Heo, H.J.M. Groen, A. Szczesna, C.-Y. Chung, T.-Y. Chao, G. Middleton, A. Zeaiter, G. Klingelschmitt, B. Klughammer, N. Thatcher,